MIssling's failure at this morning's conference call to make any useful comment or reference to the Anavex 3-71/schizophrenia study, soon to yield top line data, was deliberate, I believe. Preliminary disclosures may have been prevented for legal reasons.
All of us were eager to learn anything we could about what this study was revealing. But, not a word.
Is that because the early results are weak, or because Missling wants to lay out a full, positive report when all of the data are collected and can be presented in detail. Instead of an early, incomplete allusion to the study, there should be a full, complete report when the study actually concludes; showing incontrovertible positive efficacy and safety data. With that single announcement, Anavex Life Sciences Corp's share-price value will ascend steeply. If Anavex is able to only get Anavex 3-71 approved for schizophrenia, and all the other trials fail to produce regulatory approval for blarcamesine, the company will still be highly valued. Millions suffer from schizophrenia. When it becomes clear that Anavex 3-71 will be the new standard of care (SOC) treatment for the disease, Anavex will be a great financial success.
News 
Market Data 
Discover 
AI
